March 5, 2018 / 11:31 AM / 9 months ago

BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer

March 5 (Reuters) - G1 Therapeutics Inc:

* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER

* G1 THERAPEUTICS - CURRENTLY CONDUCTING TWO ADDITIONAL CLINICAL TRIALS OF TRILACICLIB WITH PRELIMINARY DATA FROM BOTH EXPECTED IN Q4 2018

* G1 THERAPEUTICS - TRILACICLIB REDUCED CLINICALLY RELEVANT CONSEQUENCES OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION VERSUS PLACEBO

* G1 THERAPEUTICS INC - STATISTICALLY SIGNIFICANT RESULTS FROM PHASE 2A TRIAL EVALUATING TRILACICLIB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below